At 36 months, the disease-free survival and molecular residual disease event-free rate was 86 vs 36% for patients in the osimertinib and placebo groups. HealthDay News — For patients with resected ...
MASS-FIX versus standard methods to predict for PFS and OS among multiple myeloma patients participating on the STAMINA trial. Interim analysis of a phase 2 minimal residual disease (MRD)-adaptive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback